Profilaxia das Doenças Hereditárias do Eritrócito

Pretende-se esclarecer a prevalência que as doenças hereditárias do eritrócito têm não só a nível mundial e europeu mas também ao nível do nosso país e consulta de hematologia pediátrica do Hospital Dona Estefânia. São realçados os aspectos que condicionam a morbilidade associada a estas doenças crónicas, quer do ponto de vista da sua própria evolução natural como da própria terapêutica instituida. São referidas atitudes consensuais do ponto de vista profilático e terapêutico adoptadas neste tipo de doenças crónicas. Assume-se o diagnóstico pós-natal como de extrema importância, possibilitando diagnosticar-se casais de risco e implementar medidas privilegiando o aconselhamento destes casais quanto à característica genética de que são portadores e pondo à sua disposição meios de diagnóstico seguros na caracterização da sua descendência antes do nascimento (daignóstico pré-natal), com base num estudo de biologia molecular. Conclui-se realçando os programas de prevenção, sem os quais se torna impossível o decréscimo da incidência destas doenças, nomeadamente nos países de forte prevalência.

Cicatrização de Feridas

A cicatrização de feridas constitui um processo complexo e coordenado, envolvendo a interacção entre células e vários sistemas mensageiros. Este processo pode dividir-se em 3 fases: inflamatória, proliferativa e de remodelação. O mecanismo exacto das feridas crónicas permanece ainda por esclarecer. Os avanços recentes da biologia molecular permitiram identificar moléculas que evidenciaram novos mecanismos fisiopatológicos das feridas crónicas, assim como possíveis alvos terapêuticos. Este artigo tem como objectivo uma revisão dos mecanismos envolvidos na cicatrização, pilar fundamental para a compreensão e abordagem de doentes com feridas crónicas, prática corrente em Dermatologia.

Gravidez e Amamentação. Efeitos Secundários dos Fármacos Usados no Tratamento das Doenças da Tiróide, Sobre o Feto e o Recém-Nascido

Os autores referem os efeitos secundários, sobre o feto e o recém-nascido, dos antitiroideus de síntese, dos bloqueadores ß, dos iodetos, do iodoradiactivo(131I), carbonato de lítio e tiroxina. Os fármacos mais frequentemente utilizados são os antitiroideus de síntese e a tiroxina. Os riscos dos antitiroideus estão relacionados com o facto de atravessarem a barreira placentar e poderem provocar bócio e hipotiroidismo fetais. As hormonas tiroideias maternas, que atravessam a placenta, são muito importantes para o normal desenvolvimento neuronal de feto durante o primeiro trimestre.

The Hybrid Approach for Palliation of Hypoplastic Left Heart Syndrome: Intermediate Results of a Single-Center Experience

INTRODUCTION: Hypoplastic left heart syndrome (HLHS) is a major cause of cardiac death during the first week of life. The hybrid approach is a reliable, reproducible treatment option for patients with HLHS. Herein we report our results using this approach, focusing on its efficacy, safety and late outcome. METHODS: We reviewed prospectively collected data on patients treated for HLHS using a hybrid approach between July 2007 and September 2014. RESULTS: Nine patients had a stage 1 hybrid procedure, with seven undergoing a comprehensive stage 2 procedure. One patient completed the Fontan procedure. Five patients underwent balloon atrial septostomy after the hybrid procedure; in three patients, a stent was placed across the atrial septum. There were three deaths: two early after the hybrid procedure and one early after stage two palliation. Overall survival was 66%. CONCLUSIONS: In our single-center series, the hybrid approach for HLHS yields intermediate results comparable to those of the Norwood strategy. The existence of dedicated teams for the diagnosis and management of these patients, preferably in high-volume centers, is of major importance in this condition.

Intravenous Busulfan for Autologous Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia: a Survey of 952 Patients on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Oral busulfan is the historical backbone of the busulfan+cyclophosphamide regimen for autologous stem cell transplantation. However intravenous busulfan has more predictable pharmacokinetics and less toxicity than oral busulfan; we, therefore, retrospectively analyzed data from 952 patients with acute myeloid leukemia who received intravenous busulfan for autologous stem cell transplantation. Most patients were male (n=531, 56%), and the median age at transplantation was 50.5 years. Two-year overall survival, leukemia-free survival, and relapse incidence were 67±2%, 53±2%, and 40±2%, respectively. The non-relapse mortality rate at 2 years was 7±1%. Five patients died from veno-occlusive disease. Overall leukemia-free survival and relapse incidence at 2 years did not differ significantly between the 815 patients transplanted in first complete remission (52±2% and 40±2%, respectively) and the 137 patients transplanted in second complete remission (58±5% and 35±5%, respectively). Cytogenetic risk classification and age were significant prognostic factors: the 2-year leukemia-free survival was 63±4% in patients with good risk cytogenetics, 52±3% in those with intermediate risk cytogenetics, and 37 ± 10% in those with poor risk cytogenetics (P=0.01); patients ≤50 years old had better overall survival (77±2% versus 56±3%; P<0.001), leukemia-free survival (61±3% versus 45±3%; P<0.001), relapse incidence (35±2% versus 45±3%; P<0.005), and non-relapse mortality (4±1% versus 10±2%; P<0.001) than older patients. The combination of intravenous busulfan and high-dose melphalan was associated with the best overall survival (75±4%). Our results suggest that the use of intravenous busulfan simplifies the autograft procedure and confirm the usefulness of autologous stem cell transplantation in acute myeloid leukemia. As in allogeneic transplantation, veno-occlusive disease is an uncommon complication after an autograft using intravenous busulfan.